An HSP90 inhibitor, ganetespib, has been used in combination with crizotinib in clinical research, showing an enhanced inhibitory effect on anaplastic lymphoma kinase (ALK) positive lung cancers.389,390 However, the combination drug therapies of these inhibitors also carried potential risks, including uncertain drug interactions, increased toxicity, and complex treatment management.391,392 Therefore, currently, no drugs targeting molecule chaperones have received FDA approval. Here, ALK is linked to lung cancer.